Medical Economics February 24, 2025
Key Takeaways
- Medtronic’s BrainSense aDBS system dynamically adjusts therapy based on individual brain activity, enhancing Parkinson’s disease treatment.
- The BrainSense Electrode Identifier reduces initial programming time by 85%, offering precise real-time data for tailored therapy.
- The ADAPT-PD trial evaluated the safety and effectiveness of aDBS, highlighting its potential to revolutionize Parkinson’s treatment.
- aDBS technology aims to improve symptom control for patients experiencing motor fluctuations and dyskinesias with conventional DBS.
Real-time neuromodulation offers more precise treatment for Parkinson’s patients.
Medtronic plc, a leading global health care technology company based in Galway, Ireland, has received U.S. Food and Drug Administration (FDA) approval for BrainSense Adaptive deep brain stimulation (aDBS) — the first system of its kind to dynamically adjust therapy...
Today's Sponsors
Today's Sponsor